PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia-Reference-Cited by-全球学者库

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

Published:2018-05-17 Issue:20 Volume:131 Page:2256-2261
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhang Yingchi¹,Gao Yufeng²³,Zhang Hui⁴⁵,Zhang Jingliao¹⁶⁷,He Fuhong²³,Hnízda Aleš⁸,Qian Maoxiang⁴,Liu Xiaoming¹⁶⁷,Gocho Yoshihiro⁴,Pui Ching-Hon⁹,Cheng Tao¹⁶⁷,Wang Qianfei²³,Yang Jun J.⁴⁹,Zhu Xiaofan¹⁶⁷,Liu Xin²³

Affiliation:

1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;

2. Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China;

3. University of Chinese Academy of Sciences, Beijing, China;

4. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN;

5. Department of Hematology and Oncology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China;

6. Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;

7. Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Beijing, China;

8. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic; and

9. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

Abstract

Key Points AGGF1-PDGFRB is a novel oncogenic fusion gene in Ph-like ALL. Genomic profiling and functional studies identified a novel PDGFRB mutation directly related to TKI resistance.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/20/2256/1467803/blood817510.pdf

Reference21 articles.

1. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study;Schultz;J Clin Oncol,2009

2. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia;Ohno;Curr Hematol Malig Rep,2010

3. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031;Schultz;Leukemia,2014

4. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL;Rousselot;Blood,2016

5. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement;Soverini;Cancer,2014

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitotic Catastrophe Heterogeneity: Implications for Prognosis and Immunotherapy in Hepatocellular Carcinoma;2024-01-18

2. Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms;The Journal of Molecular Diagnostics;2023-12

3. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL;Nature Communications;2023-11-17

4. Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children’s Cancer Group study ALL-2015;Annals of Hematology;2023-08-08

5. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant—review article;Annals of Hematology;2023-05-02